Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. Geller MA, et al. Cytotherapy. 2011 Jan;13(1):98-107. doi: 10.3109/14653249.2010.515582. Epub 2010 Sep 20. Cytotherapy. 2011. PMID: 20849361 Free PMC article. Clinical Trial.
Allogeneic natural killer cells for refractory lymphoma.
Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Bachanova V, et al. Cancer Immunol Immunother. 2010 Nov;59(11):1739-44. doi: 10.1007/s00262-010-0896-z. Epub 2010 Aug 3. Cancer Immunol Immunother. 2010. PMID: 20680271 Free PMC article.
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.
Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Geller MA, et al. Cancer Immunol Immunother. 2010 Dec;59(12):1877-1884. doi: 10.1007/s00262-010-0914-1. Epub 2010 Sep 5. Cancer Immunol Immunother. 2010. PMID: 20820775 Free PMC article. Clinical Trial.
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS. Bachanova V, et al. Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9. Blood. 2014. PMID: 24719405 Free PMC article. Clinical Trial.
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E. Fehniger TA, et al. Biol Blood Marrow Transplant. 2018 Aug;24(8):1581-1589. doi: 10.1016/j.bbmt.2018.03.019. Epub 2018 Mar 27. Biol Blood Marrow Transplant. 2018. PMID: 29597002 Free PMC article. Clinical Trial.
68 results